LV
LAVA Therapeutics N.V.
LVTX · NASDAQ
$1.74 -3.87% (-$0.07)
Market Cap $45.8M
P/E Ratio -
Div. Yield -
ROE 108.07%
Piotroski F-Score Weak
2/9Valuation
68 /100
Cheap P/B 3.61x
P/FCF 3.20x
P/S 9.17x
Growth
100 /100
Growing Book val. growth 134.99%
Rev. growth N/A
FCF growth N/A
Profitability
30 /100
Weak Net margin 466.43%
Op. margin 440.34%
FCF margin 286.37%
Quality
1 /100
Poor ROE 108.07%
ROA 44.83%
Asset turnover 0.10x
Debt
57 /100
Moderate Current ratio 12.27x
Int. coverage -23.12x
Net debt/EBITDA 3.38x
Stability
28 /100
Unstable EPS volatility 92.03%
Profitable years 0
Beta 0.50x
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre LVTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stephen Allen Hurly
Employees
34
Headquarters
Utrecht